NO20090305L - Cyklosporin formuleringer - Google Patents

Cyklosporin formuleringer

Info

Publication number: NO20090305L
Authority: NO; Norway
Prior art keywords: cyclosporine formulations; cyclosporine; formulations; preparations; described here
Prior art date: 2006-07-25

Application number

NO20090305A

Other languages

English (en)

Norwegian (no)

Inventor

Rhett M Schiffman

Richard S Graham

Aileen Morgan

Mayssa Attar

Walter Tien

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-25

Filing date

2009-01-20

Publication date

2009-02-24

2009-01-20 Application filed by Allergan Inc filed Critical Allergan Inc

2009-02-24 Publication of NO20090305L publication Critical patent/NO20090305L/no

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 2
108010036949 Cyclosporine Proteins 0.000 title abstract 2
229960001265 ciclosporin Drugs 0.000 title abstract 2
229930182912 cyclosporin Natural products 0.000 title abstract 2
238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20090305A 2006-07-25 2009-01-20 Cyklosporin formuleringer NO20090305L (no)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US82023906P	2006-07-25	2006-07-25
US82980806P	2006-10-17	2006-10-17
US82979606P	2006-10-17	2006-10-17
US86945906P	2006-12-11	2006-12-11
US88352507P	2007-01-05	2007-01-05
US91635207P	2007-05-07	2007-05-07
PCT/US2007/074079 WO2008014200A2 (fr)	2006-07-25	2007-07-23	Compositions de cyclosporine

Publications (1)

Publication Number	Publication Date
NO20090305L true NO20090305L (no)	2009-02-24

Family

ID=38626720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20090305A NO20090305L (no)	2006-07-25	2009-01-20	Cyklosporin formuleringer

Country Status (11)

Country	Link
US (5)	US9561178B2 (fr)
EP (2)	EP2043602B1 (fr)
JP (6)	JP2009544722A (fr)
KR (1)	KR20090053797A (fr)
AU (1)	AU2007276815B2 (fr)
BR (1)	BRPI0714727A2 (fr)
CA (1)	CA2658518A1 (fr)
IL (1)	IL196591A0 (fr)
MX (1)	MX2009000843A (fr)
NO (1)	NO20090305L (fr)
WO (1)	WO2008014200A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
AU2016203191B2 (en) *	2006-07-25	2018-03-01	Allergan, Inc.	Cyclosporin compositions
CN101918019B (zh)	2007-10-08	2014-11-26	奥里尼亚制药有限公司	包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
US20110009339A1 (en) *	2009-04-14	2011-01-13	Allergan, Inc	Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
US20100279951A1 (en) *	2009-05-01	2010-11-04	Aileen Morgan	Method of treating allergic conjunctivitis with cyclosporin compositions
CN102458370A (zh) *	2009-06-09	2012-05-16	卢克斯生物科技公司	用于眼科用途的表面药物递送系统
EP3078385A1 (fr) *	2010-05-25	2016-10-12	Allergan, Inc.	Émulsions de cyclosporine
US20130029919A1 (en)	2011-07-26	2013-01-31	Allergan, Inc.	Two part formulation system for opthalmic delivery
EP2779993B1 (fr) *	2011-11-15	2018-04-04	Allergan, Inc.	Suspensions autoclavables de la forme 2 de cyclosporine a
BR112014013820A8 (pt) *	2011-12-07	2017-06-13	Allergan Inc	distribuição lipídica eficiente a um filme lacrimal humano usando um sistema de emulsão sensível ao sal
US9907826B2 (en)	2011-12-07	2018-03-06	Allergan, Inc.	Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
FR2988297B1 (fr) *	2012-03-22	2014-03-28	Thea Lab	Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
JP2015519368A (ja)	2012-06-01	2015-07-09	アラーガンインコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	シクロスポリンａ類似体
US20140127327A1 (en) *	2012-11-08	2014-05-08	Allergan, Inc.	Preserved topical formulations with improved antimicrobial activity
CA2967413C (fr)	2014-11-25	2023-08-15	Allergan, Inc.	Compositions ophtalmiques contenant des huiles d'omega-3 stabilisees pardes antioxydants
WO2016112321A1 (fr)	2015-01-08	2016-07-14	Allergan, Inc.	Dérivés de cyclosporine dans lesquels la chaîne latérale mebmt a été cyclisée
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
JP2020152674A (ja) *	2019-03-20	2020-09-24	株式会社リコー	難水溶性化合物の可溶化物の製造方法
GR1010012B (el) *	2020-05-12	2021-05-27	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU205861B (en) *	1986-12-19	1992-07-28	Sandoz Ag	Process for producing hydrosole of pharmaceutically effective material
JP2577049B2 (ja) *	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
JPH0558906A (ja) *	1991-09-06	1993-03-09	Sankyo Co Ltd	シクロスポリン点眼製剤
HK1004520A1 (en) *	1992-05-13	1998-11-27	Novartis Ag	Ophthalmic compositions containing a cyclosporin
US5474979A (en) *	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
US5565302A (en) *	1995-04-21	1996-10-15	W. R. Grace & Co.-Conn.	Process for preparing photosensitive resin composition
ATE286403T1 (de) *	1997-03-12	2005-01-15	Abbott Lab	Hydrophile binäre systeme zur verabreichung von cyclosporin
JP2000143542A (ja) *	1998-11-10	2000-05-23	Wakamoto Pharmaceut Co Ltd	難溶性免疫抑制剤含有ｏ／ｗエマルジョン製剤
ES2206363T3 (es) *	2000-04-07	2004-05-16	Laboratoire Medidom S.A.	Formulaciones oftalmicas a base de ciclosporina, de acido hialuronico y de polisorbato.
CN1441679A (zh) *	2000-07-14	2003-09-10	阿勒根公司	包含具有提高的溶解度的治疗活性组分的组合物
KR20020050135A (ko)	2000-12-20	2002-06-26	조명재	피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
US6656460B2 (en) *	2001-11-01	2003-12-02	Yissum Research Development	Method and composition for dry eye treatment
UA79766C2 (en) *	2001-12-14	2007-07-25	Yahotech Ag	Pharmaceutical formulation comprising cyclosporin and use thereof
US20030165545A1 (en) *	2002-01-30	2003-09-04	Allergan, Inc.	Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7354574B2 (en) *	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
US20050058696A1 (en) *	2003-09-12	2005-03-17	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en) *	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US20050277584A1 (en) *	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US20050276867A1 (en) *	2004-06-09	2005-12-15	Allergan, Inc.	Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
CA2586074C (fr)	2004-11-09	2013-07-23	Novagali Pharma Sa	Emulsion ophtalmique du type huile dans eau a potentiel zeta positif stable
US20060148686A1 (en) *	2004-12-30	2006-07-06	Bausch & Lomb Incorporated	Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US7288520B2 (en)	2005-07-13	2007-10-30	Allergan, Inc.	Cyclosporin compositions
WO2007011880A2 (fr)	2005-07-18	2007-01-25	Minu, L.L.C.	Neuro-protection/neuro-stimulation oculaire amelioree
US7501393B2 (en) *	2005-07-27	2009-03-10	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
RU2008122978A (ru)	2005-11-09	2009-12-20	Комбинаторкс, Инкорпорейтед (Us)	Способы, композиции и наборы для лечения медицинских состояний
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions

2007
- 2007-07-20 US US11/781,095 patent/US9561178B2/en not_active Expired - Fee Related
- 2007-07-23 EP EP07799758.3A patent/EP2043602B1/fr not_active Not-in-force
- 2007-07-23 BR BRPI0714727-9A patent/BRPI0714727A2/pt not_active IP Right Cessation
- 2007-07-23 KR KR1020097003774A patent/KR20090053797A/ko not_active Ceased
- 2007-07-23 CA CA002658518A patent/CA2658518A1/fr not_active Abandoned
- 2007-07-23 EP EP16174365.3A patent/EP3124037A1/fr not_active Withdrawn
- 2007-07-23 JP JP2009521925A patent/JP2009544722A/ja active Pending
- 2007-07-23 AU AU2007276815A patent/AU2007276815B2/en not_active Ceased
- 2007-07-23 MX MX2009000843A patent/MX2009000843A/es not_active Application Discontinuation
- 2007-07-23 WO PCT/US2007/074079 patent/WO2008014200A2/fr not_active Ceased
2008
- 2008-02-22 US US12/035,698 patent/US20080207495A1/en not_active Abandoned
2009
- 2009-01-19 IL IL196591A patent/IL196591A0/en unknown
- 2009-01-20 NO NO20090305A patent/NO20090305L/no not_active Application Discontinuation
2013
- 2013-09-05 JP JP2013184232A patent/JP2014015471A/ja active Pending
2016
- 2016-01-07 JP JP2016002022A patent/JP2016106103A/ja active Pending
2017
- 2017-02-06 US US15/425,836 patent/US20170143792A1/en not_active Abandoned
- 2017-03-22 JP JP2017055846A patent/JP2017132790A/ja active Pending
2019
- 2019-03-05 JP JP2019039610A patent/JP2019108380A/ja active Pending
2020
- 2020-10-07 US US17/064,988 patent/US20210169971A1/en not_active Abandoned
2021
- 2021-02-12 JP JP2021020702A patent/JP2021075564A/ja active Pending
2022
- 2022-05-12 US US17/663,188 patent/US20220409693A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170143792A1 (en)	2017-05-25
JP2014015471A (ja)	2014-01-30
US20080207495A1 (en)	2008-08-28
US20080039378A1 (en)	2008-02-14
US9561178B2 (en)	2017-02-07
EP3124037A1 (fr)	2017-02-01
JP2009544722A (ja)	2009-12-17
AU2007276815A1 (en)	2008-01-31
CA2658518A1 (fr)	2008-01-31
EP2043602A2 (fr)	2009-04-08
WO2008014200A3 (fr)	2008-08-28
JP2019108380A (ja)	2019-07-04
AU2007276815B2 (en)	2013-05-09
JP2016106103A (ja)	2016-06-16
WO2008014200A2 (fr)	2008-01-31
US20210169971A1 (en)	2021-06-10
IL196591A0 (en)	2009-11-18
JP2021075564A (ja)	2021-05-20
JP2017132790A (ja)	2017-08-03
KR20090053797A (ko)	2009-05-27
US20220409693A1 (en)	2022-12-29
MX2009000843A (es)	2009-02-03
BRPI0714727A2 (pt)	2013-05-14
EP2043602B1 (fr)	2016-06-15

Publication	Publication Date	Title
NO20090305L (no)	2009-02-24	Cyklosporin formuleringer
TW200716646A (en)	2007-05-01	(S)-N-methylnaltrexone
CY1123739T1 (el)	2022-03-24	Αντισωματα anti-cd38
NO20084893L (no)	2009-01-20	Lyofiliserte terapeutiske peptistoffpreparater
DK2209375T3 (da)	2014-10-06	Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
ME01942B (me)	2015-05-20	Jedinjenja, preparati i metode
MX2009004883A (es)	2009-05-21	Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
BRPI0718146A2 (pt)	2013-11-05	Dispositivos de infusão e métodos
NO20085396L (no)	2009-02-27	Antistoffer og immunkonjugater, og anvendelser derav
DK2273975T3 (da)	2014-06-30	Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
MY148635A (en)	2013-05-15	Anti-tat226 antibodies and immunoconjugates
MX2010003045A (es)	2010-04-29	Composiciones de ciclosporina.
DK2040702T3 (da)	2011-09-05	Anvendelse af AMPK-aktiverende imidazolderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater omfattende dem
NO20092052L (no)	2009-07-24	Antistoffer og immunkonjugater, og anvendelser derav
NO20085338L (no)	2009-03-23	Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
DK2049525T3 (da)	2010-05-03	N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
EP4434550A3 (fr)	2025-02-26	Conjugués anticorps humain-médicament contre le facteur tissulaire
MY191407A (en)	2022-06-27	Certain chemical entities, compositions and methods
UY30816A1 (es)	2008-07-31	Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
ATE474617T1 (de)	2010-08-15	Medizinproduktsysteme
MX2009006327A (es)	2009-06-23	Compuestos heterociclicos y metodos de uso de los mismos.
BRPI0508894A (pt)	2007-09-11	meios para administração transdérmica de nicotina e uso
NO20062709L (no)	2006-08-11	Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
NO20090458L (no)	2009-01-28	Sukkerfrie, lagringsstabile antihistaminsaftpreparater
ATE490967T1 (de)	2010-12-15	18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate

Legal Events

Date	Code	Title	Description
2014-02-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application